Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02191878 |
Recruitment Status :
Completed
First Posted : July 16, 2014
Last Update Posted : January 16, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
This study is an open-label, multi-center, phase 1, dose escalation study with a phase 2 expansion cohort to determine the safety, pharmacokinetics and preliminary anti-tumor activity of intravenous TKM-080301 in subjects with advanced hepatocellular carcinoma (HCC).
This study is being done to:
- Test the safety and tolerability of TKM-080301 in subjects with advanced hepatocellular carcinoma
- Find the highest dose of TKM-080301 that can be given without causing side effects, called the maximum tolerated dose (MTD).
- Provide a preliminary assessment of anti-tumor activity of TKM-080301
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Hepatocellular Carcinoma Hepatoma Liver Cancer, Adult Liver Cell Carcinoma, Adult | Drug: TKM-080301 | Phase 1 Phase 2 |
Study design: Open label, multi-center, 3 + 3 dose-escalation study with an expansion cohort at the maximum tolerated dose (MTD) to investigate safety, tolerability, PK, and preliminary anti-tumor activity of TKM 080301 in subjects with HCC.
Sequential cohorts of 3 to 6 subjects will receive escalating doses of TKM 080301 according to a pre-specified dose escalation scheme. Assessment of dose-limiting toxicities (DLTs) will be made during Cycle 1 to determine the maximum tolerated dose (MTD). Once the MTD level is established, approximately 20 subjects will be enrolled in an expansion cohort to further confirm the safety and tolerability of TKM-080301 at the MTD.
Study Population: A minimum of 9 and up to approximately 18 adult male or female subjects with histologically or cytologically confirmed metastatic or locally advanced inoperable HCC and a life expectancy of 3 months or more are planned in the dose escalation phase. Approximately 20 subjects are planned in the expansion cohort.
Study Treatment: TKM-080301 will be administered by intravenous (IV) infusion, once weekly for 3 consecutive weeks followed by a 1 week rest period. This 28-day treatment period constitutes 1 cycle.
Subjects who demonstrate clinical benefit without progression per RECIST 1.1 guidelines may receive treatment beyond 6 cycles if the Investigator considers it is in the best interest of the subject, and only with the approval of the Medical Monitor. Subjects would then continue TKM 080301 therapy until withdrawal of consent, disease progression or unacceptable toxicity occurs.
Pharmacokinetics (PK) Subjects will undergo blood sample collection for PK analysis during cycles 1 and 2.
Study Duration: Each treatment cycle will have duration of 28 days and each subject will typically receive up to 6 cycles of treatment. The total duration of the study is expected to be approximately 28 months.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 43 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Open-Label, Multi-Center, Phase 1, Dose Escalation Study With Phase 2 Expansion Cohort to Determine the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma |
Study Start Date : | June 2014 |
Actual Primary Completion Date : | May 2016 |
Actual Study Completion Date : | July 2016 |
Arm | Intervention/treatment |
---|---|
Experimental: Phase 1 Escalation / Phase 2 Expansion
Phase 1 - dose escalation with intravenous infusion of TKM-080301 to determine MTD. Phase 2 - dose expansion at the MTD. |
Drug: TKM-080301
TKM-080301 intravenous infusion
Other Name: PLK1-HCC |
- Maximum tolerated dose (MTD) [ Time Frame: Up to 6 months after initial dose. ]Laboratory assessments
- Preliminary assessment of anti-tumor activity by Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1) [ Time Frame: Upon every 2 cycles of treatment for up to 6 months ]Obtain preliminary assessment of anti-tumor activity by Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1)
- Clinical Benefit Rate at maximum tolerated dose (MTD) in Expansion Cohort [ Time Frame: Upon completion of treatment of expansion cohort; up to 6 months after last participant is dosed. ]Assessed after completion of Phase 2.
- Assessment of Pharmacodynamic Effect [ Time Frame: Upon completion of cycle 1 and cycle 2 treatment; 1 and 2 months after last participant is dosed in expansion cohort. ]Assessment of target mRNA reduction in participants consenting to pre- and post-treatment tumor biopsies.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Key Inclusion Criteria:
- Child-Pugh class of A
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤5.0 × ULN
- Total bilirubin ≤3.0 mg/dL
- Platelets ≥75,000 /mL
- International Normalized Ratio (INR) ≤1.7
- Subjects must meet the protocol-defined criteria for both hepatitis B virus (HBV) and hepatitis C virus (HCV) status
Key Exclusion Criteria:
- History of significant cardiovascular disease will be excluded
- History of liver transplant.
- Diagnosis of fibrolamellar HCC or tumors of mixed histology.
- Subjects known to be positive for Human immunodeficiency virus (HIV) infection.
- Known central nervous system (CNS) or brain metastases.
- Poorly controlled ascites and/or requirement for therapeutic paracentesis more frequently than once every 3 months.
- Symptomatic encephalopathy within 3 months prior to the first dose of TKM-080301 and/or requirement for medication for encephalopathy.
- Esophageal variceal bleeding within 2 weeks prior to the first dose of TKM-080301.
- Asthma or chronic obstructive pulmonary disease (COPD) requiring daily medication.
- Prior therapy with nitrosoureas or mitomycin within 6 weeks prior to the first dose of TKM-080301.
- Prior therapy with any biologic chemotherapeutic or investigational drug within 5 half-lives or 3 weeks, whichever is longer prior to the first dose of TKM 080301.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02191878
United States, Arizona | |
Arizona Clinical Research Center | |
Tucson, Arizona, United States, 85715 | |
United States, California | |
University of California San Francisco | |
San Francisco, California, United States, 94115 | |
United States, Missouri | |
Kansas City Research Institute | |
Kansas City, Missouri, United States, 64131 | |
United States, New York | |
Memorial Sloan Kettering Cancer Center | |
New York, New York, United States, 10065 | |
United States, Texas | |
Mary Crowley Cancer Research Centers | |
Dallas, Texas, United States, 75230 | |
Canada, Ontario | |
Princess Margaret Hospital | |
Toronto, Ontario, Canada | |
China | |
Queen Mary Hospital | |
Hong Kong, China | |
Korea, Republic of | |
Seoul National University Hospital | |
Seoul, Gyeonggi-do, Korea, Republic of, 110744 | |
Samsung Medical Center | |
Seoul, Gyeonggi-do, Korea, Republic of, 135-710 | |
ASAN Medical Center | |
Seoul, Gyeonggi-do, Korea, Republic of, 138-736 | |
Severence Hospital, Yonsei, University Health System | |
Seoul, Korea, Republic of | |
Singapore | |
National University Hospital | |
Singapore, Singapore | |
Taiwan | |
National Taiwan University Hospital | |
Taipei, Taiwan | |
Taipei Medical University Hospital, Shuang-Ho Hospital | |
Taipei, Taiwan | |
Taipei Veterans General Hospital | |
Taipei, Taiwan |
Study Director: | Mark Kowalski, M.D., Ph.D. | Tekmira Pharmaceuticals |
Responsible Party: | Arbutus Biopharma Corporation |
ClinicalTrials.gov Identifier: | NCT02191878 |
Other Study ID Numbers: |
TKM-HCC-001 |
First Posted: | July 16, 2014 Key Record Dates |
Last Update Posted: | January 16, 2019 |
Last Verified: | January 2019 |
Liver Cancer Liver Neoplasms Liver Epithelial Neoplasms Liver Cancer, malignant |
Carcinoma Carcinoma, Hepatocellular Liver Neoplasms Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Adenocarcinoma Digestive System Neoplasms |
Neoplasms by Site Digestive System Diseases Liver Diseases TKM-080301 Protein Kinase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |